Table of Contents Author Guidelines Submit a Manuscript
Case Reports in Nephrology
Volume 2017, Article ID 9543079, 4 pages
https://doi.org/10.1155/2017/9543079
Case Report

Early Renal Involvement in a Girl with Classic Fabry Disease

1Servicio de Terapia Intensiva del Hospital Dr. Enrique Erill de Escobar, Provincia de Buenos Aires, Argentina
2GINEF Argentina (Grupo de Investigación Nefrológica en la Enfermedad de Fabry), Buenos Aires, Argentina
3Centro de Infusión y Estudio de Enfermedades Lisosomales del Instituto de Nefrología Clínica Pergamino, Provincia de Buenos Aires, Argentina
4Centro de Neurociencias Los Manantiales, Grupo Gamma Rosario, Provincia de Santa Fe, Argentina
5Cátedra de Biofísica y Fisiología, Instituto Universitario Italiano de Rosario, Provincia de Santa Fe, Argentina

Correspondence should be addressed to Fernando Perretta; moc.liamtoh@atterrepjf

Received 13 July 2017; Accepted 23 August 2017; Published 1 October 2017

Academic Editor: Hiro Matsukura

Copyright © 2017 Fernando Perretta et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. C. De Duve, “Exploring cells with a centrifuge,” Science, vol. 189, no. 4198, pp. 186–194, 1975. View at Publisher · View at Google Scholar · View at Scopus
  2. R. J. Desnick, Y. A. Ioannou, and C. M. Eng, “Alpha-galactosidase a deficiency: fabry disease,” in The Metabolic And Molecular Basis of Inherited Disease, C. R. Scriver, A. L. Beaudet, W. S. Sly, and D. Valle, Eds., pp. 2741–2784, McGraw-Hill, New York, 7th edition, 1995. View at Google Scholar
  3. S. Park, J. A. Kim, K. Y. Joo et al., “Globotriaosylceramide leads to KCa3.1 channel dysfunction: a new insight into endothelial dysfunction in fabry disease,” Cardiovascular Research, vol. 89, no. 2, pp. 290–299, 2011. View at Publisher · View at Google Scholar · View at Scopus
  4. R. J. Desnick, K. Y. Allen, S. J. Desnick, and etal., “Fabrys disease: enzymatic diagnosis of hemizygotes and heterozygotes: alpha-galactosidase activities in plasma, serum, urine, and leukocytes,” Journal of Laboratory and Clinical Medicine, vol. 81, pp. 157–171, 1973. View at Google Scholar
  5. R. J. Desnick, R. Brady, J. Barranger et al., “Fabry disease, an under-recognized multisystemic disorder: expert recommendations for diagnosis, management, and enzyme replacement therapy,” Annals of Internal Medicine, vol. 138, no. 4, pp. 338–346, 2003. View at Publisher · View at Google Scholar · View at Scopus
  6. A. Mehta, R. Ricci, U. Widmer et al., “Fabry disease defined: baseline clinical manifestations of 366 patients in the fabry outcome survey,” European Journal of Clinical Investigation, vol. 34, no. 3, pp. 236–242, 2004. View at Publisher · View at Google Scholar · View at Scopus
  7. R. J. Desnick, Y. A. Ioannou, and C. M. Eng, “Alpha-Galactosidase a deficiency: fabry disease,” in The Metabolic And Molecular Basis of Inherited Disease, C. R. Scriver, A. L. Beaudet, W. S. Sly, and D. Valle, Eds., pp. 3733–3774, McGraw-Hill, New York, 8th edition, 2001. View at Google Scholar
  8. P. J. Meikle, J. J. Hopwood, A. E. Clague, and W. F. Carey, “Prevalence of lysosomal storage disorders,” Journal of the American Medical Association, vol. 281, no. 3, pp. 249–254, 1999. View at Publisher · View at Google Scholar · View at Scopus
  9. G. E. Linthorst, M. G. Bouwman, F. A. Wijburg, and etal., “Screening for Fabry disease in high-risk populations: a systematic review,” Journal of Medical Genetics, vol. 47, no. 4, pp. 217–222, 2010. View at Publisher · View at Google Scholar
  10. S. Jaurretche, N. Antongiovanni, and F. Perretta, “Prevalence of chronic kidney disease in fabry disease patients: multicenter cross sectional study in Argentina,” Molecular Genetics and Metabolism Reports, vol. 12, pp. 41–43, 2017. View at Publisher · View at Google Scholar
  11. C. Tøndel, L. Bostad, A. Hirth, and E. Svarstad, “Renal biopsy findings in children and adolescents with fabry disease and minimal albuminuria,” American Journal of Kidney Diseases, vol. 51, no. 5, pp. 767–776, 2008. View at Publisher · View at Google Scholar · View at Scopus
  12. A. C. Vedder, A. Strijland, M. A. vd Bergh Weerman, S. Florquin, J. M. F. G. Aerts, and C. E. M. Hollak, “Manifestations of Fabry disease in placental tissue,” Journal of Inherited Metabolic Disease, vol. 29, no. 1, pp. 106–111, 2006. View at Publisher · View at Google Scholar · View at Scopus
  13. D. P. Germain, “Fabry disease,” Orphanet Journal of Rare Diseases, vol. 5, 2010. View at Publisher · View at Google Scholar · View at Scopus
  14. R. J. Desnick and R. O. Brady, “Fabry disease in childhood,” Journal of Pediatrics, vol. 144, no. 5, pp. S20–S26, 2004. View at Publisher · View at Google Scholar · View at Scopus
  15. D. A. Laney, D. S. Peck, A. M. Atherton et al., “Fabry disease in infancy and early childhood: a systematic literature review,” Genetics in Medicine, vol. 17, no. 5, pp. 323–330, 2015. View at Publisher · View at Google Scholar · View at Scopus
  16. A. B. Fogo, L. Bostad, E. Svarstad et al., “Scoring system for renal pathology in Fabry disease: report of the international study group of fabry nephropathy (ISGFN),” Nephrology Dialysis Transplantation, vol. 25, no. 7, pp. 2168–2177, 2010. View at Publisher · View at Google Scholar · View at Scopus
  17. C. Tøndel, T. Kanai, K. K. Larsen et al., “Foot process effacement is an early marker of nephropathy in young classic fabry patients without albuminuria,” Nephron, vol. 129, no. 1, pp. 16–21, 2015. View at Publisher · View at Google Scholar · View at Scopus
  18. C. Tøndel, B. E. Vikse, L. Bostad, and E. Svarstad, “Safety and complications of percutaneous kidney biopsies in 715 children and 8573 adults in Norway 1988–2010,” Clinical Journal of the American Society of Nephrology, vol. 7, no. 10, pp. 1591–1597, 2012. View at Publisher · View at Google Scholar · View at Scopus
  19. S. M. Rombach, N. Dekker, M. G. Bouwman, and etal., “Plasma globotriaosylsphingosine: diagnostic value and relation to clinical manifestations of Fabry disease,” Biochimica et Biophysica Acta - Molecular Basis of Disease, vol. 1802, no. 9, pp. 741–748, 2010. View at Publisher · View at Google Scholar · View at Scopus
  20. H. Trimarchi, R. Canzonieri, A. Muryan, and etal., “La identificación de podocitos urinarios. La utilidad potencial de un biomarcador novedoso de daño gomerular en las glomerulopatías primarias y secundarias. Un estudio piloto,” Revista Nefrología Argentina, vol. 14, no. 1, 2016. View at Google Scholar
  21. B. Fall, C. R. Scott, M. Mauer et al., “Urinary podocyte loss is increased in patients with fabry disease and correlates with clinical severity of fabry nephropathy,” PLoS ONE, vol. 11, no. 12, Article ID e0168346, 2016. View at Publisher · View at Google Scholar · View at Scopus
  22. W. R. Wilcox, M. Banikazemi, N. Guffon et al., “Long-term safety and efficacy of enzyme replacement therapy for Fabry disease,” American Journal of Human Genetics, vol. 75, no. 1, pp. 65–74, 2004. View at Publisher · View at Google Scholar · View at Scopus
  23. R. Skrunes, E. Svarstad, K. Kampevold Larsen, S. Leh, and C. Tøndel, “Reaccumulation of globotriaosylceramide in podocytes after agalsidase dose reduction in young Fabry patients,” Nephrology Dialysis Transplantation, vol. 32, no. 5, pp. 807–813, 2017. View at Publisher · View at Google Scholar